| Date | Ticker | Insider | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|---|
| Date | Ticker | Insider | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|---|
Insider buying and selling activity across 114 companies in the Pharmaceuticals industry. Part of the Health Care sector.
| Date | Ticker | Insider | Role | Type | Shares | Price | Value | Chg% | 3M | 12M | SEC |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Jun 10, 2022 | ZTS Zoetis Inc. | Reed Willie M55 | Director | Sell | 1,855 | $162.31 | $301,085.05 | -21.5% | -1.7% | +1.4% | |
| Jun 9, 2022 | EBS Emergent Biosolutions Inc. | Zoon Kathryn C62 | Director | Sell | 1,173 | $31.52 | $36,972.96 | -5.6% | -27.8% | -73.8% | |
| Jun 9, 2022 | CGC Canopy Growth Corp | Stewart Thomas Carlton45 | Chief Accounting Officer | Sell | 281 | $4.98 | $1,399.38 | -1.5% | -11.4% | -82.3% | |
| Jun 9, 2022 | CGC Canopy Growth Corp | Hong Judy Eun Joo66 | Chief Financial Officer | Sell | 1,021 | $4.98 | $5,084.58 | -16.7% | -11.4% | -82.3% | |
| Jun 8, 2022 | AQST Aquestive Therapeutics, Inc. | Boyd Peter E.84 | Svp-bus. Process &Info. Tech. | Buy | 2,293 | $0.96 | $2,201.28 | +4.4% | +38.6% | +138.4% | |
| Jun 8, 2022 | CBSTF Cannabist Co Holdings Inc. | Clarke Jeff | - | Buy | 25,000 | $1.75 | $43,750.00 | +5.5% | - | - | |
| Jun 8, 2022 | AQST Aquestive Therapeutics, Inc. | Barber Daniel77 | Chief Executive Officer | Buy | 91,743 | $0.96 | $88,073.28 | +90.0% | +38.6% | +138.4% | |
| Jun 8, 2022 | AQST Aquestive Therapeutics, Inc. | Braender Lori J | General Counsel | Buy | 13,761 | $0.96 | $13,210.56 | +55.0% | +38.6% | +138.4% | |
| Jun 8, 2022 | AQST Aquestive Therapeutics, Inc. | Schobel Alexander Mark83 | Chief Innovation/ Tech Officer | Buy | 45,871 | $0.96 | $44,036.16 | +5.5% | +38.6% | +138.4% | |
| Jun 8, 2022 | PCRX Pacira Biosciences, Inc. | Laranjeira Charles Anthony61 | Chief Technical Officer | Sell | 7,750 | $60.38 | $467,960.83 | -5.3% | -13.7% | -37.7% | |
| Jun 8, 2022 | ORGO Organogenesis Holdings Inc. | Erani Albert79 | 10% Owner | Sell | 170,000 | $5.43 | $923,300.00 | - | -32.3% | -22.9% | |
| Jun 8, 2022 | PCRX Pacira Biosciences, Inc. | Stack David M67 | CEO And Chairman | Sell | 25,793 | $60.56 | $1,561,998.17 | -3.4% | -13.7% | -37.7% | |
| Jun 8, 2022 | ORGO Organogenesis Holdings Inc. | Erani Albert79 | 10% Owner | Sell | 170,000 | $5.43 | $923,300.00 | - | -32.3% | -22.9% | |
| Jun 7, 2022 | HIMS Hims & Hers Health, Inc. | Maltz Jules A.72 | Director, 10% Owner | Buy | 50,000 | $3.99 | $199,500.00 | New | +47.7% | +126.2% | |
| Jun 7, 2022 | IRWD Ironwood Pharmaceuticals Inc | Currie Mark G53 | Director | Sell | 190,383 | $12.01 | $2,286,499.83 | -24.3% | -13.1% | -4.8% | |
| Jun 7, 2022 | TLPH Talphera, Inc. | Angotti Vincent J.56 | Chief Executive Officer | Buy | 46,400 | $0.22 | $10,333.28 | +4.8% | +28.3% | -74.4% | |
| Jun 7, 2022 | PFE Pfizer Inc | Damico Jennifer B.58 | SVP &Controller | Sell | 4,218 | $53.96 | $227,603.28 | -28.0% | -14.5% | -26.7% | |
| Jun 7, 2022 | PCRX Pacira Biosciences, Inc. | Molloy Anthony74 | Chief Lgl &Compliance Officer | Sell | 5,550 | $60.79 | $337,367.72 | -12.1% | -17.8% | -39.8% | |
| Jun 7, 2022 | PCRX Pacira Biosciences, Inc. | Reinhardt Max79 | President, Rest Of World | Sell | 5,250 | $61.66 | $323,736.56 | -9.3% | -17.8% | -39.8% | |
| Jun 7, 2022 | PCRX Pacira Biosciences, Inc. | Williams Kristen Marie76 | Chief Administrative Officer | Sell | 8,618 | $60.37 | $520,255.40 | -21.2% | -17.8% | -39.8% | |
| Jun 6, 2022 | PCRX Pacira Biosciences, Inc. | Winston Roy68 | Chief Medical Officer | Sell | 17,546 | $61.39 | $1,077,135.48 | -4.5% | -15.5% | -35.6% | |
| Jun 6, 2022 | PCRX Pacira Biosciences, Inc. | McLoughlin Dennis64 | Chief Customer Officer | Sell | 2,140 | $61.37 | $131,340.36 | -6.3% | -15.5% | -35.6% | |
| Jun 6, 2022 | PCRX Pacira Biosciences, Inc. | Reinhart Charles A. III64 | Chief Financial Officer | Sell | 2,516 | $61.37 | $154,416.98 | -8.2% | -15.5% | -35.6% | |
| Jun 6, 2022 | PCRX Pacira Biosciences, Inc. | Slonin Jonathan72 | Chief Clinical Officer | Sell | 362 | $61.37 | $22,217.39 | -1.3% | -15.5% | -35.6% | |
| Jun 6, 2022 | BMY Bristol Myers Squibb Co | Leung Sandra | EVP, General Counsel | Sell | 65,000 | $74.89 | $4,867,850.00 | -17.4% | -8.1% | -11.7% |
The blue line has two modes, toggled with the Relative and Absolute buttons:
Relative (default) shows cumulative industry performance with both the overall market and parent sector movements removed. When the line rises above 100, the industry is outperforming its sector; below 100 means underperforming. This is calculated using factor returns via weighted least squares (WLS) regression, isolating pure industry-specific behavior.
Absolute shows the total cumulative return of the industry including market and sector movement. This reflects what an investor actually experienced — an industry can show strong absolute gains even while underperforming its sector in relative terms.
Both views start at an index of 100. Other return drivers such as momentum, value, or size are deliberately retained in both modes, since these are part of what makes an industry behave the way it does and may reflect the conditions insiders are responding to.